News Conference News AHA 2025 Evolocumab Cuts MACE Risk in Patients Without Prior MI, Stroke: VESALIUS-CV Michael O'Riordan November 08, 2025
News Conference News AHA 2023 ESPRIT: Intensive BP-Lowering Reduces MACE in Chinese Patients Todd Neale November 13, 2023
News Conference News AHA 2022 Pemafibrate Fails to Lower CVD Risk in Patients With High Triglycerides: PROMINENT Michael O'Riordan November 05, 2022
News Conference News AHA 2019 Apabetalone Falls Short in Diabetic ACS Patients With Low HDL: BETonMACE Yael L. Maxwell November 21, 2019
News Conference News AHA 2018 EMPA-HEART Offers Mechanistic Clues for Empagliflozin’s Cardiac Benefits Michael O'Riordan November 16, 2018
News Conference News AHA 2018 Long-term FREEDOM: At Nearly 8 years, CABG Maintains Mortality Benefit Over PCI Michael O'Riordan November 14, 2018
News Conference News AHA 2018 AHA 2018: New Cholesterol Guidelines, Fish Oil, Diabetes Meds, and Inflammation Blow Into the Windy City Shelley Wood November 05, 2018
News Conference News AHA 2014 FACTOR-64: No Benefit to CTA Screening of Asymptomatic Patients with Diabetes November 16, 2014
News Conference News AHA 2012 AHA 2012: Multiple Studies Provide Clinical Guidance for Interventional Community Jason Kahn November 11, 2012
News Conference News AHA 2012 EMPIRE: Exenatide Cardioprotective in STEMI Patients Receiving DES Jason Kahn November 04, 2012